Provider review
RX Bella review: it names the right trials, then puts a sixteen-month result at month six
RX Bella does something most sellers won't: it names the trials its numbers come from, gives the journal and the year, and says plainly that they're averages rather than promises. Then its own timeline puts STEP 1's roughly 15% at month six. That result took 68 weeks. The tirzepatide page does the same thing with a 72-week figure. And under the heading about keeping weight off long term, it credits SUSTAIN — which is the diabetes program, not the weight-loss one. The right trials, cited wrongly.
Some links on this site are affiliate links, and we may earn a commission. How we’re paid
Visit RX BellaOf RX Bella’s 3 dated product claims documented below, 0 are consistent with the cited evidence. Among the dated prices documented below, the lowest listed upfront charge is $199 for 30 days (GLP-1 Microdose protocol, monthly). A matching claim does not mean the compounded product was tested or FDA-approved.
Names the right trials, with the journal and the year, and then puts their 68- and 72-week results at month six.
Worth trusting if
- You want a seller that names the trials behind its numbers rather than quoting them from nowhere
- You want the sentence that these are averages and not a promise, which this site does print
Be skeptical if
- You are planning around the timeline, which puts results roughly a year earlier than the trials found them
- You are buying the microdose protocol and want to know what is in it
- You want to know which company you are contracting with, or which pharmacy fills the prescription
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Not confirmed
None found
Provenance
Products reviewed at RX Bella
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection — $249 a month, though every price on this site is written as a starting figure.
- Compounded tirzepatide injection — $299 a month as a starting figure, the dearest of the four products.
- GLP-1 Microdose protocol — $199 a month, and the figure RX Bella puts in its site-wide banner.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
2
Products with human evidence
For the advertised use, out of 3 products reviewed here. The evidence concerns the molecule, not RX Bella's service.
2
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from RX Bella’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Compounded semaglutide injectionSemaglutide · Compounded (503A)Claim reaches past the trials
“03 MONTH 6 ~15% Average body weight reduction reported in published trials. 04 YEAR 1+ Maintained. Most members sustain results with continued physician-directed treatment. Outcomes referenced from STEP 1 and SUSTAIN clinical trial data.”
Read on the RX Bella site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in 1,961 adults. Reported a mean weight reduction of about 15% on semaglutide 2.4 mg. The figure is the result at the END of 68 weeks, not a milestone at six months.
The number is right and the clock is wrong. STEP 1 reported roughly 15% mean weight reduction after 68 weeks — about sixteen months of treatment. RX Bella's timeline puts that same figure at month six, which is a little over a third of the way through the trial. The site also contradicts itself: a paragraph further down the same page correctly describes the evidence as covering "roughly 24-72 weeks". Separately, the maintenance step credits "STEP 1 and SUSTAIN" — but SUSTAIN is the semaglutide diabetes program, a different indication at a lower dose, and STEP is the weight-management one. RX Bella names both programs correctly elsewhere on the same page, which is what makes this a slip rather than a misunderstanding.1
Compounded tirzepatide injectionTirzepatide · Compounded (503A)Claim reaches past the trials
“STAGE 03 Combined metabolic effect. The dual mechanism produces the highest average weight loss recorded in any GLP-1-class clinical trial to date. 03 MONTH 6 ~20% Average body weight reduction in published trials. Outcomes referenced from SURMOUNT-1 trial data.”
Read on the RX Bella site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks in 2,539 adults at 5, 10 and 15 mg once weekly. The roughly 20% mean reduction is the result at the top dose at the END of 72 weeks.
Same shape as the semaglutide page. SURMOUNT-1's roughly 20% mean reduction is a 72-week result at the top dose, and RX Bella's timeline places it at month six. The trial is correctly named and correctly attributed, which is more than most sellers manage — the error is entirely in when the result is said to arrive. The superlative in the stage description is a separate matter and we do not file it as wrong: among approved medicines in this class, SURMOUNT-1's figure is the highest published. It is stated with no date and no scope on a field that keeps moving.2
GLP-1 Microdose protocolGLP-1 (molecule not named) · Compounded (503A)No trial supports this claim
“A lower-dose GLP-1 protocol designed for metabolic health, body composition, and appetite recalibration — not aggressive weight loss. […] Microdosing applies the same GLP-1 receptor mechanism at a lower therapeutic dose — preserving the metabolic and appetite-recalibration benefits while softening the trade-offs. […] Many of GLP-1's positive effects on metabolism, inflammation, and appetite signaling are preserved at lower doses.”
Read on the RX Bella site, September 2026
No trial for this use
No trial can be matched to this product because RX Bella never says what is in it. Searched on September 13, 2026 across every page of its own site — the homepage, all three treatment pages, the terms, the privacy notice and the product data behind the homepage: the words semaglutide and tirzepatide appear nowhere in connection with the microdose protocol, and no dose is given. A trial record cannot be attached to an unnamed molecule, and guessing which one it is would be inventing the evidence base.
This is the only product whose contents are never stated. "A lower-dose GLP-1 protocol" names a drug class, not a drug. The page is candid that it is "not aggressive weight loss", and it excludes patients with significant weight to lose, which is fair. But it goes on to say that the benefits of GLP-1 medicines are "preserved at lower doses", and that is the claim no trial supports. Microdosing GLP-1 medicines is not what any of the trials studied — STEP 1 and SURMOUNT-1 both titrated participants up to a maintenance dose and measured them there — so even a named molecule at a lower dose would not inherit those results. With the molecule unnamed, there is nothing at all to weigh the claim against.
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named. RX Bella's footer describes the arrangement at the level of a category — the platform "facilitates access to independent, U.S.-licensed clinical providers and state-licensed compounding pharmacies" — and names neither the doctors nor the pharmacy. Nothing on the site says whether the medication is made to order under a prescription or dispensed ready-made. What the same disclaimer does say, plainly and without hedging, is that compounded medications are not FDA-approved and that their safety, efficacy and quality have not been independently verified by the FDA. That sentence is better than most of this market manages, and it sits on every page.
Read on the RX Bella site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
No certificate of analysis, potency, purity or sterility result appears anywhere. The trust signals are social instead: "10k+ Trusted by thousands of members" with no date attached, an average care rating shown as a bare figure, before-and-after photographs marked "individual results vary", and member stories quoting specific weight losses. Against that, RX Bella does two unusually careful things — it names the trials its outcome figures come from, with the journal and year, and it says in the same breath that they "reflect what GLP-1 therapy can do on average, not a guaranteed result".
Read on the RX Bella site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
RX Bella says telehealth nationwide on its treatment pages and publishes no list of states, no exclusions and no fifty-state claim, on the homepage, the three treatment pages or the terms.
Read the full licensing claim
No company is named anywhere on the site — the footer is a copyright line, and the terms and privacy pages give no business name, address or state. No clinician is named either; every product says only that it is reviewed by a licensed provider.
Read on the RX Bella site, September 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
Assessment
What holds up, and what does not
- It names the trials behind its outcome figures — STEP 1 and SURMOUNT-1 — with the journal and the year.
- It says the figures are averages rather than a promise, in the same paragraph as the figures.
- Its disclaimer states plainly that compounded medications are not FDA-approved.
Show 4 more
- Its maintenance claim is honestly conditional, resting on continued treatment rather than a lasting cure.
- Its contraindication note is specific rather than generic, naming medullary thyroid carcinoma and MEN 2.
- One paragraph describes the evidence base correctly, as covering roughly 24 to 72 weeks.
- No FDA warning letter.
- Its timeline puts STEP 1's roughly 15% at month six, when that was the result after 68 weeks.
- The tirzepatide page does the same, placing a 72-week figure at month six.
- The same page contradicts itself, describing the evidence elsewhere as covering roughly 24 to 72 weeks.
Show 7 more
- It credits SUSTAIN for weight maintenance, but SUSTAIN is the diabetes program, not the weight-loss one.
- The microdose protocol never names its molecule or its dose, anywhere on the site.
- Its page says the benefits of GLP-1 medicines are "preserved at lower doses", which no published trial has tested.
- No pharmacy is named, and nothing says whether the medication is made to order or dispensed ready-made.
- No company is named — the terms and privacy pages give no business name, address or state.
- No clinician is named anywhere.
- "10k+ trusted by thousands of members" carries no date and no source.
Verdict
The bottom line
The evidence posture here is better than most and the execution slips twice. If you are using RX Bella's timeline to decide whether this is working, add about a year to it: the figures it shows at month six are what the trials found at sixteen and eighteen months. And if you are buying the microdose protocol, ask what molecule is in it before you do.
Opens RX Bella's website. A link is not a recommendation to take anything.
What the starting price leaves to confirm
The October 13 homepage describes prices as starting figures confirmed after provider review and says an applicant who is not approved pays nothing. Neither statement establishes the price of your prescribed dose, the term of a prepaid plan or whether an approved order can later be refunded. 3
Ask for the molecule, formulation, total due now and renewal amount in writing. The current site also links a peptide-therapy catalog; that broader catalog does not make its GLP-1 trial citations evidence for every peptide. Our older claims and prices retain their individual verification dates, and we have not tested the intake.
Full analysis — 4 more sectionsIt cites its trials. That's rare. · Then the timeline · The wrong trial · The product it won't describe
It cites its trials. That's rare.
Most sellers in this market quote a weight-loss percentage from nowhere. RX Bella doesn't. On its semaglutide page:
"…published clinical trials of the active ingredients — semaglutide (STEP program, N Engl J Med 2021) and tirzepatide (SURMOUNT-1, N Engl J Med 2022) — over roughly 24–72 weeks alongside diet and activity."
And immediately after:
"They reflect what GLP-1 therapy can do on average, not a guaranteed result; individual outcomes vary."
Both trials named. Both journals right. Both years right. The range — 24 to 72 weeks — is right too. That paragraph is better than almost anything else we've graded.
Then the timeline
A few inches above it, a four-step strip headed "What to Expect":
01 MONTH 1 Titration
02 MONTH 3 Established
03 MONTH 6 ~15% Average body weight reduction reported in published trials
04 YEAR 1+ Maintained
STEP 1 randomized 1,961 adults and reported a mean reduction of about 15% — at 68 weeks. 1 That's sixteen months. The strip puts it at six.
The tirzepatide page runs the same layout with ~20% at month 6. SURMOUNT-1's roughly 20% is the top-dose result at 72 weeks. 2
So the same page tells you two different things. One paragraph says 24 to 72 weeks. The strip says month six. A reader looking at a timeline, which is what a timeline is for, gets the wrong one.
The wrong trial
Under step 04, the maintenance step:
"Outcomes referenced from STEP 1 and SUSTAIN clinical trial data."
STEP is the weight-management program. SUSTAIN is the diabetes program — a different indication, a different population, and a lower dose than the 2.4 mg used for weight loss.
What makes this worth flagging rather than shrugging at is that RX Bella gets it right elsewhere on the same page, where it names STEP and SURMOUNT-1 correctly. It knows the difference. The maintenance step reaches for a trial that doesn't study maintenance of weight loss.
The product it won't describe
RX Bella's GLP-1 Microdose protocol has a page of its own. It opens:
"A lower-dose GLP-1 protocol designed for metabolic health, body composition, and appetite recalibration — not aggressive weight loss."
That names a class, not a drug. The page goes on for several screens, through mechanism, candidacy, timeline and side effects, and never names a molecule or a dose. Neither does the homepage, the other treatment pages, the terms or the privacy notice.
Some of it is careful. It says outright that this is not aggressive weight loss, and it lists "patients with significant weight to lose" as people who would be better served elsewhere. Then it makes the claim that matters:
"Many of GLP-1's positive effects on metabolism, inflammation, and appetite signaling are preserved at lower doses."
Nothing published shows that, and the product wouldn't inherit the trial results even if it were named. STEP 1 and SURMOUNT-1 both titrated participants up to a maintenance dose and measured them there. A deliberately lower dose is a different treatment, and nothing published tells you what it does.
Questions
Frequently asked questions
Will I lose 15% of my body weight in six months?
The trial that figure comes from took 68 weeks to reach it. STEP 1 reported a mean reduction of roughly 15% at the end of about sixteen months of treatment, and RX Bella's timeline places the same number at month six. Its own text elsewhere on the page describes the evidence as covering 24 to 72 weeks, which is the accurate version.
Is SUSTAIN the right trial for weight loss?
No. SUSTAIN is the semaglutide type 2 diabetes program — a different indication, a different population, and a lower dose than the 2.4 mg used for weight management. STEP is the weight-loss program, and RX Bella cites it correctly a few lines away on the same page.
What's in the microdose protocol?
RX Bella doesn't say. It describes the product only as a lower-dose GLP-1 protocol, with no molecule and no dose named anywhere on the site. Its own page prints no price, and it's the least described product on the site.
Would a lower dose give the same results?
Nothing published tells you. Both major trials titrated participants up to a maintenance dose and measured them there, so results from a deliberately lower dose aren't covered by either. It's a reasonable thing for a seller to offer and an unreasonable thing to price off trial figures.
Who makes the medication?
RX Bella doesn't name a pharmacy. Its disclaimer describes the arrangement in general terms — independent licensed doctors and state-licensed compounding pharmacies — without naming either, and nothing says whether the medication is made to order or dispensed ready-made. It does say clearly that compounded medications aren't FDA-approved.
Glossary
Key terms
Show definitions
- STEP vs SUSTAIN
- Two different semaglutide trial programs. STEP tested it for weight management at 2.4 mg a week; SUSTAIN tested it for type 2 diabetes at lower doses. Results from one do not transfer to the other.
- Titration
- Starting at a low dose and stepping up over weeks to a target. Both major weight-loss trials titrated participants up and measured results at the maintenance dose, not on the way there.
- Compounded
- Made to order by a pharmacy for an individual patient rather than manufactured and approved as a finished product. Compounded drugs are not FDA-approved and the FDA has not evaluated their safety, effectiveness or quality.
Compare
Others selling what RX Bella sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists RX Bella is on
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off RX Bella's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 3 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 adults, mean weight reduction of about 15% reported at 68 weeks. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 adults at 5, 10 and 15 mg, results reported at 72 weeks. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
- Publisher (2026). Public buyer information checked October 13, 2026. Public primary source. the RX Bella site
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.